PHS
RNAM

PFM Health Sciences’s Avidity Biosciences RNAM Stock Holding History

PFM Health Sciences’s Portfolio RNAM Stock Details RNAM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-441,155
Closed -$11M – 101
2020
Q3 		$11M Buy
+441,155
New +$12.7M 0.51% 58

Other funds holding RNAM

RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
ACM
Alethea Capital Management Mercer Island, Washington $195M AUM 51.17% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
MCMC
Matrix Capital Management Company Portsmouth, New Hampshire $46.3M AUM 114.38% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

PFM Health Sciences's RNAM Position: Q4 2020 in Review

PFM Health Sciences sold out of Avidity Biosciences (RNAM) in Q4 2020, closing a stake of 441,155 shares — an estimated $11M sold.

PFM Health Sciences first reported a position in RNAM in Q3 2020 and held it in 1 quarter. The position peaked at $11M in Q3 2020. 82 funds tracked by Wall St. Rank hold RNAM as of Q4 2020.

  • PFM Health Sciences reported no remaining Avidity Biosciences position as of Q4 2020 after selling out during the quarter.
  • PFM Health Sciences sold 441,155 Avidity Biosciences shares in Q4 2020, an estimated $11M.
  • PFM Health Sciences first reported a position in Avidity Biosciences in Q3 2020 and held it in 1 quarter.
  • PFM Health Sciences's Avidity Biosciences position peaked at $11M in Q3 2020.
  • 82 funds tracked by Wall St. Rank held Avidity Biosciences as of Q4 2020.

Based on PFM Health Sciences's 13F filing for Q4 2020, filed 16 Feb 2021.